Kim Jung-Sun, Jeong Tae-Young, Cho Chong Kwan, Lee Yeon-Weol, Yoo Hwa Seung
East-West Cancer Center, Dunsan Oriental Medical Hospital, Daejeon University, Daejeon, Korea.
J Acupunct Meridian Stud. 2010 Sep;3(3):181-7. doi: 10.1016/S2005-2901(10)60034-9.
This experimental study was performed to investigate the antitumor effect of skin of venenum bufonis (SVB) in NCI-H460 human lung cancer cell xenografted nude mice. NCI-H460 cell lines were cultured and then xenografted into nude mice. Mice were divided into four groups: SVB (0.25 mg/kg) given orally, SVB (0.25 mg/kg) interperitoneally, SVB (0.5 mg/kg) interperitoneally, and the untreated group. Mice were raised and treated for 28 days. Body weight and tumor weight and volumes were measured daily. Absolute organ weight, microhistological observations and biochemical blood analyses were performed on the final day of the study following the sacrificing of these animals. Tumor inhibition rate, mean survival time and percent increase in life span were also calculated. Tumor size decreased in all SVB treated mice. Increasing the dose of SVB attenuated the inhibition rate seen on the 11th day of this experiment. Furthermore, tumor weight and volume in the mice treated with the highest dose of SVB were the smallest. Mice treated with high-dose intraperitoneal SVB gained weight and had significantly smaller spleens compared with untreated mice. Mean survival time and percent increase in life span in the low-dose intraperitoneal SVB treatment group were higher than those of other groups. Biochemical blood analysis revealed that phosphatase and urea nitrogen levels were decreased significantly in 0.25 mg/kg SVB orally treated mice (p < 0.01). Blood level calcium and alanine transaminase significantly decreased with intraperitoneal SVB 0.5 mg/kg (p < 0.05). The findings of this in vivo study suggest that SVB may have potential as a tumor growth inhibitor. Further research that overcomes the limitations of this study to determine the antitumor mechanism of SVB is still required.
本实验研究旨在探讨蟾皮对NCI-H460人肺癌细胞异种移植裸鼠的抗肿瘤作用。培养NCI-H460细胞系,然后将其异种移植到裸鼠体内。将小鼠分为四组:口服蟾皮(0.25mg/kg)组、腹腔注射蟾皮(0.25mg/kg)组、腹腔注射蟾皮(0.5mg/kg)组和未治疗组。饲养并治疗小鼠28天。每天测量体重、肿瘤重量和体积。在处死这些动物后的研究最后一天进行绝对器官重量、微观组织学观察和血液生化分析。还计算了肿瘤抑制率、平均生存时间和寿命延长百分比。所有接受蟾皮治疗的小鼠肿瘤大小均减小。增加蟾皮剂量可减弱本实验第11天观察到的抑制率。此外,接受最高剂量蟾皮治疗小鼠的肿瘤重量和体积最小。与未治疗小鼠相比,高剂量腹腔注射蟾皮治疗的小鼠体重增加,脾脏明显较小。低剂量腹腔注射蟾皮治疗组的平均生存时间和寿命延长百分比高于其他组。血液生化分析显示,口服0.25mg/kg蟾皮治疗的小鼠磷酸酶和尿素氮水平显著降低(p<0.01)。腹腔注射0.5mg/kg蟾皮可使血钙和谷丙转氨酶水平显著降低(p<0.05)。这项体内研究的结果表明,蟾皮可能具有作为肿瘤生长抑制剂的潜力。仍需要进一步研究以克服本研究的局限性,从而确定蟾皮的抗肿瘤机制。